公开(公告)号：US20040120893A1

公开(公告)日：2004-06-24

申请号：US10706659

申请日：2003-11-12

Inventor： Joseph L. Witztum ,  Sotirios Tsimikas ,  Wulf Palinski ,  Peter X. Shaw

IPC: A61K051/00

CPC classification number: G01N33/92 ,  A61K41/0057 ,  A61K49/227 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/77 ,  G01N2800/323 ,  Y10S436/808 ,  Y10S436/809 ,  Y10S436/811 ,  Y10S530/807

Abstract: The invention provides a novel human Mab Fab, cloned by phage display, and its use in diagnostic and therapeutic methods. In particular the invention provides a method for analyzing the OxLDL components of atherosclerotic plaques in vivo and a means to determine their relative pathology. As the method is based on a human Fab rather than a mouse Mab, the progress or regression of the disease may be monitored over time. The antibody may also be used for the analysis of surgical or serum samples ex vivo for the presence of OxLDL. The antibody may also be used to target therapeutic agents to the site of atherosclerotic plaques or may have use as a therapeutic agent itself.

Abstract translation: 本发明提供了一种通过噬菌体展示法克隆的新型人类Mab Fab及其在诊断和治疗方法中的应用。 特别地，本发明提供了一种用于分析体内动脉粥样硬化斑块的OxLDL组分的方法和用于确定其相对病理学的方法。 由于该方法基于人Fab而不是小鼠Mab，所以随着时间的推移可以监测疾病的进展或消退。 该抗体还可用于离体外分析外周血或血清样品以存在OxLDL。 抗体还可以用于将治疗剂靶向动脉粥样硬化斑块的位点，或者可以用作治疗剂本身。

公开(公告)号：US20040071632A1

公开(公告)日：2004-04-15

申请号：US10705448

申请日：2003-11-11

Inventor： Joseph L. Witztum ,  Sotirios Tsimikas ,  Wulf Palinski ,  Peter X. Shaw

IPC: A61K051/00

CPC classification number: G01N33/92 ,  A61K41/0057 ,  A61K49/227 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/77 ,  G01N2800/323 ,  Y10S436/808 ,  Y10S436/809 ,  Y10S436/811 ,  Y10S530/807

Abstract: The invention provides a novel human Mab Fab, cloned by phage display, and its use in diagnostic and therapeutic methods. In particular the invention provides a method for analyzing the OxLDL components of atherosclerotic plaques in vivo and a means to determine their relative pathology. As the method is based on a human Fab rather than a mouse Mab, the progress or regression of the disease may be monitored over time. The antibody may also be used for the analysis of surgical or serum samples ex vivo for the presence of OxLDL. The antibody may also be used to target therapeutic agents to the site of atherosclerotic plaques or may have use as a therapeutic agent itself.

Abstract translation: 本发明提供了一种通过噬菌体展示法克隆的新型人类Mab Fab及其在诊断和治疗方法中的应用。 特别地，本发明提供了一种用于分析体内动脉粥样硬化斑块的OxLDL组分的方法和用于确定其相对病理学的方法。 由于该方法基于人Fab而不是小鼠Mab，所以随着时间的推移可以监测疾病的进展或消退。 该抗体还可用于离体外分析外周血或血清样品以存在OxLDL。 抗体还可以用于将治疗剂靶向动脉粥样硬化斑块的位点，或者可以用作治疗剂本身。

公开(公告)号：US20040057991A1

公开(公告)日：2004-03-25

申请号：US10667931

申请日：2003-09-22

Inventor： Poh K. Hui ,  John E. Bishop ,  Eleodoro S. Madrigal JR.

IPC: A61K009/127

CPC classification number: A61K49/226 ,  A61B8/00 ,  A61K9/1277 ,  A61K47/10 ,  A61K47/24 ,  A61K49/227

Abstract: The present invention describes processes for the preparation of a lipid blend and a uniform filterable phospholipid suspension containing the lipid blend, such suspension being useful as an ultrasound contrast agent.

Abstract translation: 本发明描述了制备脂质混合物的方法和含有脂质混合物的均匀的可滤过磷脂悬浮液，该悬浮液可用作超声造影剂。

公开(公告)号：US06592846B1

公开(公告)日：2003-07-15

申请号：US09570841

申请日：2000-05-12

Applicant: Michel Schneider ,  Feng Yan ,  Pascal Grenier ,  Jérôme Puginier ,  Marie-Bernadette Barrau

Inventor： Michel Schneider ,  Feng Yan ,  Pascal Grenier ,  Jérôme Puginier ,  Marie-Bernadette Barrau

IPC: A61B800

CPC classification number: A61K49/227 ,  A61K49/223 ,  Y10S977/788 ,  Y10S977/929

Abstract: One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003.

Abstract translation: 通过使用作为填充气体的填充气体，其在水中的溶解度（以标准条件下以升水表示）以平方根除以水的平均根数，可以赋予在压力下对用作造影剂的气体填充微泡在压力下的突出抗压力， 分子量不超过0.003。

公开(公告)号：US06585955B1

公开(公告)日：2003-07-01

申请号：US08740653

申请日：1996-10-31

Applicant: Michel Schneider ,  Feng Yan ,  Pascal Grenier ,  Jérôme Puginier ,  Marie-Bernadette Barrau

Inventor： Michel Schneider ,  Feng Yan ,  Pascal Grenier ,  Jérôme Puginier ,  Marie-Bernadette Barrau

IPC: A61B800

CPC classification number: A61K49/227 ,  A61K49/223 ,  Y10S977/788 ,  Y10S977/929

Abstract: One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard conditions, divided by the square root of the molecular weight does not exceed 0.003.

公开(公告)号：US20030039613A1

公开(公告)日：2003-02-27

申请号：US10108284

申请日：2002-03-26

Inventor： Evan C. Unger ,  Thomas A. Fritz ,  Terry Matsunaga ,  VaradaRajan Ramaswami ,  David Yellowhair ,  Guanli Wu

IPC: A61K051/00 ,  A61K049/00

CPC classification number: A61K9/127 ,  A61K9/1277 ,  A61K9/1278 ,  A61K41/0028 ,  A61K41/0052 ,  A61K47/6925 ,  A61K49/223 ,  A61K49/227 ,  A61M5/3145

Abstract: Targeted therapeutic delivery systems comprising gas- or gaseous precursor-filled lipid microspheres comprising a therapeutic are described. Methods for employing such microspheres in therapeutic delivery applications are also provided. Targeted therapeutic delivery systems comprising gas- or gaseous precursor-filled liposomes having a drug encapsulated therein are preferred. Methods of and apparatus for preparing such liposomes and methods for employing such liposomes in therapeutic delivery applications are also disclosed.

Abstract translation: 描述了包含含有治疗剂的气体或气体前体填充的脂质微球的靶向治疗递送系统。 还提供了在治疗性递送应用中使用这种微球的方法。 包含气体或气态前体填充的脂质体的靶向治疗递送系统是优选的。 还公开了制备这种脂质体的方法和装置以及在治疗性递送应用中使用这种脂质体的方法。

公开(公告)号：US06443898B1

公开(公告)日：2002-09-03

申请号：US08485998

申请日：1995-06-07

Applicant: Evan C. Unger ,  Thomas A. Fritz ,  Terry Matsunaga ,  VaradaRajan Ramaswami ,  David Yellowhair ,  Guanli Wu

Inventor： Evan C. Unger ,  Thomas A. Fritz ,  Terry Matsunaga ,  VaradaRajan Ramaswami ,  David Yellowhair ,  Guanli Wu

IPC: A61B800

CPC classification number: A61K41/0028 ,  A61K9/127 ,  A61K9/1277 ,  A61K9/1278 ,  A61K41/0052 ,  A61K47/6911 ,  A61K47/6925 ,  A61K49/1815 ,  A61K49/22 ,  A61K49/223 ,  A61K49/227 ,  A61M5/3145 ,  Y10S977/904 ,  Y10S977/907

Abstract: Therapeutic delivery systems comprising gaseous precursor-filled microspheres comprising a therapeutic are described. Methods for employing such microspheres in therapeutic delivery applications are also provided. Therapeutic delivery systems comprising gaseous precursor-filled liposomes having encapsulated therein a contrast agent or drug are preferred. Methods of and apparatus for preparing such liposomes and methods for employing such liposomes in therapeutic delivery applications are also disclosed.

Abstract translation: 描述包含含有治疗剂的气态前体填充微球的治疗递送系统。 还提供了在治疗性递送应用中使用这种微球的方法。 优选包含气体前体填充脂质体的包封造影剂或药物的治疗递送系统。 还公开了制备这种脂质体的方法和装置以及在治疗性递送应用中使用这种脂质体的方法。

公开(公告)号：US06424857B1

公开(公告)日：2002-07-23

申请号：US09458007

申请日：1999-12-10

Applicant: Paul Mark Henrichs ,  Henry Raphael Wolfe

Inventor： Paul Mark Henrichs ,  Henry Raphael Wolfe

IPC: A61B706

CPC classification number: A61K49/0043 ,  A61K49/0002 ,  A61K49/0013 ,  A61K49/0021 ,  A61K49/0032 ,  A61K49/0034 ,  A61K49/0041 ,  A61K49/0065 ,  A61K49/0078 ,  A61K49/0084 ,  A61K49/0093 ,  A61K49/0438 ,  A61K49/0466 ,  A61K49/22 ,  A61K49/223 ,  A61K49/227

Abstract: The invention relates inter alia to a method of generating information from an animate human or non-human animal body which method comprises: administering to said body a physiologically tolerable material capable of absorbing, scattering or emitting light at a wavelength in the range 300 to 1300 nm; subjecting at least a portion of said body to ultrasound irradiation; detecting light in the wavelength range 300 to 1300 nm from said portion of said body; and manipulating the detected light to generate said information.

Abstract translation: 本发明特别涉及从动物人或非人动物体产生信息的方法，该方法包括：向所述身体施用能够吸收，散射或发射波长在300至1300范围内的光的生理上可耐受的材料 nm; 对所述身体的至少一部分进行超声波照射; 从所述主体的所述部分检测在300至1300nm的波长范围内的光; 并操纵检测到的光以产生所述信息。

公开(公告)号：US20020031476A1

公开(公告)日：2002-03-14

申请号：US09941395

申请日：2001-08-28

Inventor： Leo A. Trevino ,  Ernest George Schutt ,  David H. Klein ,  Thomas E. Tarara ,  Jeffry G. Weers ,  Alexey Kabalnov

IPC: A61K049/22

CPC classification number: A61K49/223 ,  A61K49/227

Abstract: A gas emulsion forming composition comprising a dry, hollow, particulate, approximately microspherical material permeated with a gas or gas mixture, which upon dissolution in aqueous liquid forms a gas emulsion comprising a plurality of bubbles surrounded by a layer of at least a first and a second surfactant, wherein the first surfactant consists essentially of a phospholipid or mixture of phospholipids having at least one acyl chain which comprises at least 10 carbon atoms, and comprising at least about 5% w/w of total surfactant, and wherein the second surfactant may or may not be a phospholipid and is more water soluble than the first surfactant; kits for preparing such microbubbles; and methods for using such microbubbles as contrast agents.

Abstract translation: 一种气体乳液形成组合物，其包含渗透有气体或气体混合物的干燥，中空，微粒，近似微球的材料，其在溶解在水性液体中时形成气体乳液，所述气体乳液包含多个气泡，所述泡沫被至少第一和第 第二表面活性剂，其中第一表面活性剂基本上由磷脂或具有至少一个包含至少10个碳原子的酰基链，并且包含至少约5％w / w的总表面活性剂的磷脂的混合物组成，并且其中第二表面活性剂可以 或者可能不是磷脂并且比第一表面活性剂更可溶于水; 用于制备这种微泡的试剂盒; 以及使用这种微泡作为造影剂的方法。

公开(公告)号：US20020028179A1

公开(公告)日：2002-03-07

申请号：US09919433

申请日：2001-07-30

Inventor： Ernest G. Schutt ,  Charles David Anderson ,  David P. Evitts

IPC: A61K049/22

CPC classification number: A61K49/227 ,  A61K49/223 ,  G02B6/0006

Abstract: A microbubble preparation formed of a plurality of microbubbles comprising a first gas and second gas surrounded by a membrane such as a surfactant, wherein the first gas and the second gas are present in a molar ration of from about 1:100 to abut 1000:1, and wherein the first gas has a vapor pressure of at least about (760nullX) mm Hg at 37null C., where x is the vapor pressure of the second gas at 37null C., and wherein the vapor pressure of each of the first and second gases is greater than about 75 mm Hg at 37null C.; also disclosed are methods for preparing microbubble compositions, including compositions that rapidly shrink from a first average diameter to a second average diameter less than about 75% of the first average diameter and are stabilized at the second average diameter; methods and kits for preparing microbubbles; and methods for using such microbubbles as contrast agents.

Abstract translation: 由多个微泡形成的微泡制品，其包含第一气体和被诸如表面活性剂的膜包围的第二气体，其中第一气体和第二气体以约1:100至约1000:1的摩尔比率存在 ，并且其中所述第一气体在37℃下具有至少约（760-X）mm Hg的蒸汽压，其中x是所述第二气体在37℃的蒸汽压，并且其中每个 的第一和第二气体在37℃下大于约75mm Hg。 还公开了制备微泡组合物的方法，包括从第一平均直径快速收缩至小于第一平均直径的约75％的第二平均直径的组合物，并且稳定在第二平均直径; 制备微泡的方法和试剂盒; 以及使用这种微泡作为造影剂的方法。